Century Therapeutics Inc (IPSC)

Currency in USD
2.070
+0.050(+2.48%)
Closed·
2.130+0.060(+2.90%)
·
IPSC is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
2.0202.085
52 wk Range
0.4353.040
Key Statistics
Prev. Close
2.02
Open
2.05
Day's Range
2.02-2.085
52 wk Range
0.435-3.04
Volume
330.59K
Average Volume (3m)
1.2M
1-Year Change
282.4834%
Book Value / Share
1.29
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
IPSC Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
4.750
Upside
+129.47%
Members' Sentiments
Bearish
Bullish
ProTips
Quickly burning through cash

Century Therapeutics Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Buy
Technical Indicators
Strong Buy
Moving Averages
Strong Buy

Analyst Ratings

4 Buy
1 Hold
0 Sell
Ratings:
5 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 4.750
(+129.47% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Mizuho
Buy8.00+286.47%-New CoverageMay 26, 2026
H.C. Wainwright
Buy5.00+141.55%2.00MaintainApr 21, 2026
Leerink Partners
Hold2.00-3.38%-MaintainMar 13, 2026
TD Cowen
Buy---New CoverageFeb 25, 2026
Clear Street
Buy6.60+218.84%-MaintainFeb 12, 2026

Earnings

Latest Release
Aug 12, 2026
EPS / Forecast
-0.17 / -0.11
Revenue / Forecast
-- / --
EPS Revisions
Last 90 days

IPSC Income Statement

Compare IPSC to Peers and Sector

Metrics to compare
IPSC
Peers
Sector
Relationship
P/E Ratio
−3.4x−3.7x−0.4x
PEG Ratio
0.02−0.060.00
Price/Book
1.6x2.6x2.6x
Price / LTM Sales
-14.6x3.1x
Upside (Analyst Target)
117.4%219.4%48.9%
Fair Value Upside
Unlock10.2%6.2%Unlock

Century Therapeutics, Inc., a biotechnology company, engages in the development of allogeneic cell therapies for the treatment of solid tumor, hematological malignancies, and autoimmune diseases. Its lead product candidate is CNTY-813, an iPSC-derived beta islet cell replacement therapy engineered with Allo-Evasion 5.0 for the treatment of type 1 diabetes. The company is also involved in the development of CNTY-308, a CD19-targeted CD4+/CD8+ CAR-iT cell therapy engineered with Allo-Evasion 5.0 as a potential treatment for B-cell-mediated autoimmune diseases; and CNTY-101, an allogeneic, iPSC-derived CAR-iNK cell therapy with six precision gene edits engineered to express CD19 CAR, with Allo-Evasion 1.0 edits designed for the treatment of CD19 for B-cell mediated autoimmune diseases. Century Therapeutics, Inc. was incorporated in 2018 and is headquartered in Philadelphia, Pennsylvania.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
15.04M8.31%31.13M
Other Institutional Investors
241.40M91.69%499.70M
Public Companies & Retail Investors
0.000.00%0.00
Total
256.44M100.00%530.83M

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
RA Capital Management, L.P.9.81%17,754,43036,752
TCG Crossover Management, LLC9.81%17,754,43036,752

People Also Watch

61.46
KGS
+1.42%
17.630
ERAS
+3.22%
111.10
DNTH
+1.45%
9.48
BIOA
-2.17%

FAQ

What Is the Century Therapeutics (IPSC) Stock Price Today?

The Century Therapeutics stock price today is 2.070 USD.

What Stock Exchange Does Century Therapeutics Trade On?

Century Therapeutics is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Century Therapeutics?

The stock symbol for Century Therapeutics is "IPSC."

What Is the Century Therapeutics Market Cap?

As of today, Century Therapeutics market cap is 374.830M USD.

What Is Century Therapeutics's Earnings Per Share (TTM)?

The Century Therapeutics EPS (TTM) is -0.766.

When Is the Next Century Therapeutics Earnings Date?

Century Therapeutics will release its next earnings report on Nov 05, 2026.

From a Technical Analysis Perspective, Is IPSC a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Century Therapeutics Stock Split?

Century Therapeutics has split 0 times.

How Many Employees Does Century Therapeutics Have?

Century Therapeutics has 78 employees.

What is the current trading status of Century Therapeutics (IPSC)?

As of Aug 23, 2026, Century Therapeutics (IPSC) is trading at a price of 2.070 USD, with a previous close of 2.020 USD. The stock has fluctuated within a day range of 2.020 USD to 2.085 USD, while its 52-week range spans from 0.435 USD to 3.040 USD.

What Is Century Therapeutics (IPSC) Price Target According to Analysts?

The average 12-month price target for Century Therapeutics is 4.750 USD, with a high estimate of 8 USD and a low estimate of 2 USD. 4 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +129.47% Upside potential.

What Is the IPSC Premarket Price?

IPSC's last pre-market stock price is 2.120 USD. The pre-market share volume is 1,920.000, and the stock has decreased by 0.100, or 4.950%.

What Is the IPSC After Hours Price?

IPSC's last after hours stock price is 2.130 USD, the stock has decreased by 0.060, or 2.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.